Michael L Haas, MD | Tower Health

Dr. Michael L. Haas

Claim this profile

Reading Hospital

Studies Lung Cancer
Studies Prostate Adenocarcinoma
12 reported clinical trials
44 drugs studied

Area of expertise

1Lung Cancer
Michael L. Haas has run 3 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage I
ALK positive
2Prostate Adenocarcinoma
Michael L. Haas has run 3 trials for Prostate Adenocarcinoma.

Affiliated Hospitals

Image of trial facility.
Reading Hospital

Clinical Trials Michael L. Haas is currently running

Image of trial facility.

Lomustine + Standard Therapy

for Glioblastoma

This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria

More about Michael L. Haas

Clinical Trial Related3 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Michael L. Haas has experience with
  • Intensity-Modulated Radiation Therapy
  • Cisplatin
  • Atezolizumab
  • Stereotactic Body Radiation Therapy
  • Nivolumab
  • Image Guided Radiation Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Michael L. Haas specialize in?
Is Michael L. Haas currently recruiting for clinical trials?
Are there any treatments that Michael L. Haas has studied deeply?
What is the best way to schedule an appointment with Michael L. Haas?
What is the office address of Michael L. Haas?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security